D R Clemmons

University of North Carolina at Chapel Hill, North Carolina, United States

Are you D R Clemmons?

Claim your profile

Publications (280)1635.06 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Budesonide is a high-potency, second-generation corticosteroid designed to minimize systemic adverse consequences of conventional corticosteroids. We performed 2 randomized, phase 3 trials to evaluate the ability of a budesonide rectal foam formulation, designed to optimize retention and provide uniform delivery of budesonide to the rectum and distal colon, in patients with ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). Two identically designed, randomized, double-blind, placebo-controlled trials evaluated the efficacy of budesonide foam for induction of remission in 546 patients with mild to moderate UP or UPS who received budesonide foam 2 mg/25 mL twice daily for 2 weeks, then once daily for 4 weeks, or placebo. Remission at week 6 occurred significantly more frequently among patients receiving budesonide foam than placebo (Study 1, 38.3% vs 25.8%; P=.0324; Study 2, 44.0% vs 22.4%; P<.0001). A significantly greater percentage of patients receiving budesonide foam vs placebo achieved rectal bleeding resolution (Study 1, 46.6% vs 28.0%; P=.0022; Study 2, 50.0% vs 28.6%; P=.0002) and endoscopic improvement (Study 1, 55.6% vs 43.2%; P=.0486; Study 2, 56.0% vs 36.7%; P=.0013) at week 6. Most adverse events occurred at similar frequencies between groups, although events related to changes in cortisol values were reported more frequently with budesonide foam. There were no cases of clinically symptomatic adrenal insufficiency. Budesonide rectal foam was well tolerated and more efficacious than placebo in inducing remission in patients with mild-moderate UP and UPS. ClinicalTrials.gov numbers: NCT01008410 and NCT01008423. Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.
    Gastroenterology 01/2015; 148(4). DOI:10.1053/j.gastro.2015.01.037 · 16.72 Impact Factor
  • David Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A major limitation in determining the effects of growth hormone (GH) therapy on overall health has been the duration of studies, which have previously ranged from 1 year to 5 years. Elbornsson et al. now report the outcome of 15 years of GH treatment on body composition and lipid profile in patients with GH deficiency, but some questions remain unanswered.
    Nature Reviews Endocrinology 03/2013; 9(6). DOI:10.1038/nrendo.2013.68 · 13.28 Impact Factor
  • Source
    David R Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin-like growth factor-I (IGF-I) is closely related to insulin but has distinct metabolic actions. IGF-I is an important stimulant of protein synthesis in muscle, but it also stimulates free fatty acid use. The administration of IGF-I to patients with extreme insulin resistance results in improvement in glycemic control, and IGF-I is associated with lowering glucose and enhancing insulin sensitivity in Type 1 and Type 2 diabetes. However, patients with diabetes are also sensitive to stimulation of side effects in response to IGF-I. IGF-I coordinately links growth hormone and insulin actions and has direct effects on intermediary metabolism.
    Endocrinology and metabolism clinics of North America 06/2012; 41(2):425-43, vii-viii. DOI:10.1016/j.ecl.2012.04.017 · 3.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Global deletion of the Igfbp2 gene results in the suppression of bone turnover. To investigate the role of insulin-like growth factor-binding protein-2 (IGFBP-2) in regulating osteoclast differentiation, we cultured Igfbp2(-/-) bone marrow cells and found a reduction in the number of osteoclasts and impaired resorption. Addition of full-length IGFBP-2 restored osteoclast differentiation, fusion, and resorption. To determine the molecular domains of IGFBP-2 that were required for this effect to be manifest, Igfbp2(-/-) bone marrow cells were transfected with constructs in which the heparin-binding (HBD) or the IGF-binding domains of IGFBP-2 were mutated. We found that both domains were necessary for osteoclastogenesis because expression of the mutated forms of either domain failed to support the formation of functionally mature osteoclasts. To discern the mechanism by which IGFBP-2 regulates osteoclast formation, PTEN abundance and phosphorylation status as well as AKT responsiveness to IGF-I were analyzed. Igfbp2(-/-) cells had elevated levels of PTEN and phospho-PTEN compared with controls. Expression of wild-type IGFBP-2 reduced the level of PTEN to that of wild-type cells. Cells expressing the IGF-binding mutant showed suppression of PTEN and phospho-PTEN equivalent to the wild-type protein, whereas those expressing the IGFBP-2 HBD mutant showed no PTEN suppression. When the ability of IGF-I to stimulate AKT activation, measured by Thr³⁰⁸ and Ser⁴⁷³ phosphorylation, was analyzed, stimulation of Ser⁴⁷³ in response to IGF-I in preosteoclasts required the presence of intact IGFBP-2. This effect was duplicated by the addition of a CK2 inhibitor that prevents the phosphorylation of PTEN. In contrast, in fully differentiated osteoclasts, stimulation of Thr³⁰⁸ phosphorylation required the presence of intact IGFBP-2. We conclude that IGFBP-2 is an important regulator of osteoclastogenesis and that both the heparin- and the IGF-binding domains of IGFBP-2 are essential for the formation of fully differentiated and functional osteoclasts.
    Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 02/2012; 27(2):390-400. DOI:10.1002/jbmr.545 · 6.83 Impact Factor
  • Source
    L A Maile · K Gollahon · C Wai · G Byfield · M E Hartnett · D Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: We have previously shown that the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS-1) regulates the response of cells, including osteoclasts, osteoblasts, smooth muscle and retinal endothelial cells, to IGF-I. Here we sought to: (1) determine whether the regulation of IGF-I responsiveness by the association of IAP with SHPS-1 is a generalised response of endothelial cells; (2) identify the mechanism by which this association contributes to changes in endothelial cell responses to IGF-I; and (3) determine whether inhibition of this association alters pathophysiological changes occurring in vivo. Endothelial cells were maintained in 5 mmol/l glucose and at hyperglycaemic levels, and exposed to an anti-IAP antibody that disrupts the association between IAP and SHPS-1. A rodent model of diabetes with endothelial cell dysfunction was used to investigate the role of the association of IAP with SHPS-1 in endothelial cell function in vivo. Endothelial cells maintained in 5 mmol/l glucose showed constitutive cleavage of the extracellular domain of IAP (which contains the SHPS-1 binding site), with no association between IAP and SHPS-1 being detected. In contrast, hyperglycaemia inhibited IAP cleavage, allowing IAP to associate with SHPS-1 and IGF-I to stimulate SHPS-1 tyrosine phosphorylation. Exposure to the anti-IAP antibody inhibited IGF-I-stimulated tube formation and increased permeability. In the rodent model, basal IAP-SHPS-1 association was not detected in retinal extracts from normal rats, but was fully restored in rats with diabetes. The anti-IAP antibody inhibited the association of IAP with SHPS-1, and reduced retinal vascular permeability and leucocyte adherence to levels similar to those in non-diabetic rats. The antibody also significantly inhibited the aberrant neovascularisation induced by hypoxia. Our results demonstrate that the increased association of IAP with SHPS-1 contributes to the pathophysiological changes in the endothelium that are induced by hyperglycaemia and hypoxia.
    Diabetologia 12/2011; 55(3):835-44. DOI:10.1007/s00125-011-2416-x · 6.67 Impact Factor
  • David R. Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The insulin-like growth factor-I receptor (IGF-IR) is present in many types of tumor cells. Additionally, some tumors show upregulation of IGF-IR number or constitutive activation. There is a great deal of interest in determining whether drugs that target the IGF receptors, such as anti-IGF-IR antibodies, can inhibit tumor cell proliferation or induce tumor cell apoptosis. The studies in cells in culture and those conducted using xenografts of tumors in animals have shown that anti-IGF-IR antibodies are very effective in inhibiting tumor cell growth. The initial human trials have not shown definitive evidence of tumor shrinkage in a large number of patients; however, subsets of patients particularly those with sarcomas have shown some responsiveness. Current studies are seeking to determine whether administration of this antibody in combination with traditional chemotherapy and/or other antibodies targeting other types of growth factor receptors can lead to improved responses. Additionally, targeting downstream signaling elements in conjunction with the IGF-IR is also being utilized as an alternative approach. The larger trials that are ongoing are likely to resolve these issues and determine the ultimate efficacy of this agent in cancer chemotherapy. This chapter focuses on antibodies directed toward the IGF-1R. The use of tyrosine kinase inhibitors as an alternative approach is discussed elsewhere in this book.
    Insulin-like Growth Factors and Cancer, 09/2011: pages 193-213;
  • [Show abstract] [Hide abstract]
    ABSTRACT: IGF-I is structurally related to proinsulin and when administered to human subjects it enhances insulin sensitivity. However because of its growth promoting properties and its relationship to growth hormone, it has been proposed as a etiologic factor in the development of diabetic complications. This review discusses recently published data regarding the ability of hyperglycemia to sensitize cells that are capable of dedifferentiating to the growth promoting effects of IGF-I. Under normoglycemic conditions vascular smooth muscle and endothelial cells are cystostatic and stimulation of the IGF-I receptor activates the adaptor protein IRS-1 which leads to PI-3 kinase pathway activation. Following exposure to hyperglycemia these cell types undergo a signaling switch whereby an entirely different mechanism is utilized to activate both the PI-3 kinase and the MAP pathways. This leads to increased cell proliferation and migration. This molecular mechanism involves the coordinate regulation of signaling molecules and scaffolding proteins. Activation of this alternative signaling mechanism is directly linked to the stimulation of pathophysiologic processes that are involved in the pathogenesis of both diabetic retinopathy and atherosclerosis. Inhibition of activation of these intermediates has been shown to attenuate glucose induced pathophysiologic changes and results in the inhibition of both atherosclerotic lesion progression and diabetic retinopathy. In summary, hyperglycemia induces a signaling switch in vascular endothelial and smooth muscle cells that results in enhanced sensitivity to the growth promoting effects of IGF-I. This may be an important variable for determining the progression of atherosclerosis in poorly controlled diabetes and in the development of retinopathy.
    Current diabetes reviews 06/2011; 7(4):235-45. DOI:10.2174/157339911796397848
  • David R. Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The sections in this article are:1Gene Structures1.1Insulin-Like Growth Factor Binding Protein 11.2Insulin-Like Growth Factor Binding Protein 21.3Insulin-Like Growth Factor Binding Protein 31.4Insulin-Like Growth Factor Binding Protein 41.5Insulin-Like Growth Factor Binding Protein 51.6Insulin-Like Growth Factor Binding Protein 61.7Acid Labile Subunit2Protein Structures2.1Insulin-Like Growth Factor Binding Protein 12.2Insulin-Like Growth Factor Binding Protein 22.3Insulin-Like Growth Factor Binding Protein 32.4Insulin-Like Growth Factor Binding Protein 42.5Insulin-Like Growth Factor Binding Protein 52.6Insulin-Like Growth Factor Binding Protein 62.7Insulin-Like Growth Factor Binding Protein-Related Proteins3Control of Gene Expression, Synthesis, and Secretion of Insulin-Like Growth Factor Binding Proteins by Cells and Tissues3.1Tissue Expression3.2Secretion by Cells In Vitro4Variables that Regulate Pericellular Abundanbce of Insulin-Like Growth Factor Binding Proteins4.1Proteolysis4.2Phosphorylation of Insulin-Like Growth Factor Binding Proteins4.3Binding to Cell Surfaces and to Extracellular Matrix5Regulation of Insulin-Like Growth Factor Actions in vitro and in vivo5.1Regulation of Half-Life5.2Modulation of Insulin-Like Growth Factor Actions5.3Specific Functions of Each Form of Binding Protein5.4A Unified Theory of the Mechanism of Action of Insulin-Like Growth Factor Binding Proteins in Connective Tissue Cells5.5Use of Insulin-Like Growth Factor Analogs5.6Related Proteins6Control of Insulin-Like Growth Factor Binding Protein Concentrations in Physiologic Fluids6.1Methodologic Considerations6.2Detection of Insulin-Like Growth Factor Binding Proteins in Physiologic Fluids Other than Blood6.3Regulation of Insulin-Like Growth Factor Binding Proteins in Serum6.4Regulation of Insulin-Like Growth Factor Binding Proteins by Hormones7Summary
    Comprehensive Physiology, 01/2011; , ISBN: 9780470650714
  • L. A. Maile · K. Gollahon · L. Allen · C. Wai · P. Dunbar · D. Clemmons ·

    Growth Hormone & IGF Research 12/2010; 20. DOI:10.1016/S1096-6374(10)70089-7 · 1.41 Impact Factor
  • L. A. Maile · P. Dunbar · D. Clemmons ·

    Growth Hormone & IGF Research 12/2010; 20. DOI:10.1016/S1096-6374(10)70155-6 · 1.41 Impact Factor
  • L. A. Maile · C. Wai · C. Rosen · D. Clemmons · K. Gollahon · L. Allen ·

    Growth Hormone & IGF Research 12/2010; 20. DOI:10.1016/S1096-6374(10)70201-X · 1.41 Impact Factor
  • Source
    Shoshana Yakar · Hayden-William Courtland · David Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin-like growth factor-1 (IGF-1) plays a central role in cellular growth, differentiation, survival, and cell cycle progression. It is expressed early during development and its effects are mediated through binding to a tyrosine kinase receptor, the insulin-like growth factor-1 receptor (IGF-1R). In the circulation, the IGFs bind to IGF-binding proteins (IGFBPs), which determine their bioavailability and regulate the interaction between the IGFs and IGF-1R. Studies in animal models and in humans have established critical roles for IGFs in skeletal growth and development. In this review we present new and old findings from mouse models of the IGF system and discuss their clinical relevance to normal and pathological skeletal physiology.
    Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 12/2010; 25(12):2543-52. DOI:10.1002/jbmr.234 · 6.83 Impact Factor
  • David R Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Measurement of serum growth hormone (GH) and insulin-like growth factor-I (IGF-) is used to monitor the degree of improvement that occurs following treatment of patients with acromegaly. Improvement in GH assay sensitivity has led to changes in the definition of normal GH however many studies that assess the predictive value of GH were conducted in an era where assays were less sensitive. Other problems that have occurred with GH measurements include utilization of different standards and failure to prove commutability of commonly accepted standard. GH reference ranges vary in their quality and are not stratified for age, sex or body mass index. IGF-I measurements are associated with similar problems. They do not use a common standard that has been proven to be commutable and results can vary widely when the same specimens are assayed in different laboratories. Although age and sex stratified reference ranges exist, these do not always have adequate numbers of subjects and BMI adjusted ranges are not available. These problems have led to significant discordance in a significant number of patients wherein the IGF-I and GH values may yield a discrepant prediction of disease stabilization. In these cases in general the IGF-I values correlate better with the presence of persistent symptoms. Patients who fail to suppress GH to normal but have a normal IGF-I have to be monitored carefully for recurrence but usually do not require further therapy if they are asymptomatic. For the long term assessment of outcome and clinical disease activity measurement of both hormones is recommended.
    Clinica chimica acta; international journal of clinical chemistry 11/2010; 412(5-6):403-9. DOI:10.1016/j.cca.2010.11.008 · 2.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperglycemia has been shown to induce the p66shc expression leading to increased reactive oxygen species (ROS) generation and apoptosis. In the present study, we demonstrated that hyperglycemia induced p66shc expression in vascular smooth muscle cells. This induction was associated with an increase in apoptosis as assessed by the increase of capspase-3 enzymatic activity, cleaved caspase-3 protein, and the number of dead cells. The ability of IGF-I to inhibit apoptosis was also attenuated. Further studies showed that hyperglycemia-induced p66shc inhibited IGF-I-stimulated phosphoinositide (PI)-3 kinase and AKT activation. Mechanistic studies showed that knockdown of p66shc enhanced IGF-I-stimulated SHPS-1/p85, p85/SHP-2, and p85/Grb2 association, all of which are required for PI-3 kinase/AKT activation. These responses were attenuated by overexpression of p66shc. IGF-I-stimulated p85 and AKT recruitment to the cell membrane fraction was altered in the same manner. Disruption of p66shc-Src interaction using either a blocking peptide or by expressing a p66shc mutant that did not bind to Src rescued IGF-I-stimulated PI-3 kinase/AKT activation as well as IGF-I-dependent cell survival. Although the highest absolute level of ROS was detected in p66shc-overexpressing cells, the relative increase in ROS induced by hyperglycemia was independent of p66shc expression. Taken together, our data suggest that the increase in p66shc that occurs in response to hyperglycemia is functioning to inhibit IGF-I-stimulated signaling and that the incremental increase in SMC sensitivity to IGF-I stimulation that occurs in response to p66shc induction of ROS is not sufficient to overcome the inhibitory effect of p66shc on Src kinase activation.
    Endocrinology 08/2010; 151(8):3611-23. DOI:10.1210/en.2010-0242 · 4.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Age-related osteoporosis is accompanied by an increase in marrow adiposity and a reduction in serum insulin-like growth factor-1 (IGF-1) and the binding proteins that stabilize IGF-1. To determine the relationship between these proteins and bone marrow adiposity, we evaluated the adipogenic potential of marrow-derived mesenchymal stromal cells (MSCs) from mice with decreased serum IGF-1 due to knockdown of IGF-1 production by the liver or knock-out of the binding proteins. We employed 10-16-week-old, liver-specific IGF-1-deficient, IGFBP-3 knock-out (BP3KO) and acid-labile subunit knock-out (ALSKO) mice. We found that expression of the late adipocyte differentiation marker peroxisome proliferator-activated receptor gamma was increased in marrow isolated from ALSKO mice. When induced with adipogenic media, MSC cultures from ALSKO mice revealed a significantly greater number of differentiated adipocytes compared with controls. MSCs from ALSKO mice also exhibited decreased alkaline-phosphatase positive colony size in cultures that were stimulated with osteoblast differentiation media. These osteoblast-like cells from ALSKO mice failed to induce osteoclastogenesis of control cells in co-culture assays, indicating that impairment of IGF-1 complex formation with ALS in bone marrow alters cell fate, leading to increased adipogenesis.
    Journal of Biological Chemistry 12/2009; 285(7):4709-14. DOI:10.1074/jbc.M109.041913 · 4.57 Impact Factor
  • Jan Frystyk · Pamela Freda · David R Clemmons ·
    [Show abstract] [Hide abstract]
    ABSTRACT: For almost three decades, the measurement of circulating IGF-I has constituted a highly important biochemical tool in the management of GH disorders. In fact, in acromegaly the importance of circulating IGF-I has increased following the introduction of the GH receptor antagonist pegvisomant, as the use of this drug makes it impossible to use circulating GH as a monitor of disease activity. In addition, determination of circulating IGF-I constitutes a valuable scientific tool in various research areas, from epidemiological investigations through clinical trials and experimental studies. The multiple facets of IGF-I physiology and patho-physiology may explain why numerous endocrine laboratories have invested in IGF-I assays, by means of either in-house assays or commercial kits. However, despite its widespread use, the measurement of IGF-I is by no means trivial. On the contrary, the pronounced binding of IGF-I to the high-affinity IGF-binding proteins (IGFBPs) constitutes a notorious source of error, which has necessitated the development of methods that more or less successfully circumvent interference from the IGFBPs. Furthermore, there are some unsolved issues with the international standardization of the different IGF-I assays and there is no consensus regarding the procedures used when collecting and storing samples for measurement of circulating IGF-I. The aim of this review is to discuss the current state of the art of IGF-I immunoassays and to present the current analytical problems with IGF-I measurements. Finally, we would like to suggest an agenda that may be used when trying to produce internationally accepted uniform requirements for future IGF-I assays.
    Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 10/2009; 20(1):8-18. DOI:10.1016/j.ghir.2009.09.004 · 1.41 Impact Factor
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone formation is regulated by osteoblast (OB) and osteoclast (OC) cells. The association between the extracellular domains of integrin associated protein (IAP, CD47) and SHPS-1 (MFR) has been reported to regulate OC differentiation. We have demonstrated that this association is regulated by the cleavage of IAP. IAP null mice have reduced OC function yet decreased bone mineral density. We hypothesize that this phenotype indicates IAP may also function as a regulator of OB differentiation. Objectives: To determine a role for IAP in OB differentiation. Methods: The preosteoblast cell lines MC3T3-E4 and MC3T3-E24 (high and low osteogenic potential respectively) were maintained for 8 days in osteogenic medium containing L-ascorbic acid and Beta-glycerophosphate. Cultures were stained for alkaline phosphatase to assess OB differentiation. Parallel cultures were lysed and IAP was visualized by western immunoblotting using an anti-IAP antibody that discriminates between intact and fragmented IAP. Differentiation was also induced in the presence of factors that protect IAP from cleavage (osteopontin [1.4ug/uL], thrombospondin [1ug/mL]) and an anti-IAP antibody that accelerates IAP cleavage (B6H12 [1ug/mL]). Results: Osteogenic medium induced increased detection of intact IAP in the E4 but not the E24 cells. In the absence of osteogenic medium, both cell lines failed to differentiate and IAP was entirely fragmented. E24 cells that were incubated with osteopontin or thrombospondin showed a 171% and 243% increase respectively in the number of alkaline phosphatase positive cells and an increase in the amount of intact IAP. E4 cells incubated with B6H12 exhibited a 69% decrease in the number of alkaline phosphatase positive cells and a decrease in the amount of intact IAP. Conclusion: These data support the hypothesis that the modulation of IAP cleavage is important in OB differentiation and suggests the phenotype of the IAP null mice reflects a disruption in OB and OC formation. NIH# HL56850
    IADR General Session 2009; 04/2009
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating patients with acromegaly. EVIDENCE/CONSENSUS PROCESS: Goals of treatment and the appropriate imaging and biochemical and clinical monitoring of patients with acromegaly were enunciated, based on the available published evidence. The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.
    The Journal of Clinical Endocrinology and Metabolism 03/2009; 94(5):1509-17. DOI:10.1210/jc.2008-2421 · 6.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Serum insulin-like growth factor (IGF) -1 is secreted mainly by the liver and circulates bound to IGF-binding proteins (IGFBPs), either as binary complexes or ternary complexes with IGFBP-3 or IGFBP-5 and an acid-labile subunit (ALS). The purpose of this study was to genetically dissect the role of IGF-1 circulatory complexes in somatic growth, skeletal integrity, and metabolism. Phenotypic comparisons of controls and four mouse lines with genetic IGF-1 deficits-liver-specific IGF-1 deficiency (LID), ALS knockout (ALSKO), IGFBP-3 (BP3) knockout, and a triply deficient LID/ALSKO/BP3 line-produced several novel findings. 1) All deficient strains had decreased serum IGF-1 levels, but this neither predicted growth potential or skeletal integrity nor defined growth hormone secretion or metabolic abnormalities. 2) IGF-1 deficiency affected development of both cortical and trabecular bone differently, effects apparently dependent on the presence of different circulating IGF-1 complexes. 3) IGFBP-3 deficiency resulted in increased linear growth. In summary, each IGF-1 complex constituent appears to play a distinct role in determining skeletal phenotype, with different effects on cortical and trabecular bone compartments.
    The FASEB Journal 11/2008; 23(3):709-19. DOI:10.1096/fj.08-118976 · 5.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin-like growth factor-I (IGF-I) and IGF binding proteins (IGFBPs) are trophic factors for cartilage and have been shown to be chondroprotective in animal models of osteoarthritis (OA). IGFBP-5 is degraded in joint fluid and inhibition of IGFBP-5 degradation has been shown to enhance the trophic effects of IGF-I. To determine the identity of IGFBP-5 protease activity in human OA joint fluid. OA joint fluid was purified and the purified material was analyzed by IGFBP-5 zymography. Both crude joint fluid and purified material contained a single band of proteolytic activity that cleaved IGFBP-5. Immunoblotting of joint fluid for complement 1s (C1s) showed a band that had the same Mr estimate, e.g., 88 kDa. In gel tryptic digestion and subsequent peptide analysis by LC-MS/MS showed that the band contained human C1s. A panel of protease inhibitors was tested for their ability to inhibit IGFBP-5 cleavage by the purified protease. Three serine protease inhibitors, FUT175 and CP-143217 and CB-349547 had IC50's between 1 and 6 microM. Two other serine protease inhibitors had intermediate activity (e.g., IC50's 20-40 microM) and MMP inhibitors had no detectible activity at concentrations up to 300 microM. Human OA fluid contains a serine protease that cleaves IGFBP-5. Zymography, immunoblotting and LC-MS/MS analysis indicate that C1s is the protease that accounts for this activity.
    Osteoarthritis and Cartilage 11/2008; 17(4):547-55. DOI:10.1016/j.joca.2008.08.004 · 4.17 Impact Factor

Publication Stats

23k Citations
1,635.06 Total Impact Points


  • 1981-2015
    • University of North Carolina at Chapel Hill
      • • Department of Medicine
      • • Division of Endocrinology and Metabolism
      • • Department of Pediatrics
      North Carolina, United States
    • Massachusetts General Hospital
      • Department of Medicine
      Boston, Massachusetts, United States
  • 2008
    • University of Tennessee at Chattanooga
      Chattanooga, Tennessee, United States
  • 2001
    • Sahlgrenska University Hospital
      Goeteborg, Västra Götaland, Sweden
  • 2000
    • Inonu University
      • Turgut Özal Medical Center
      Malatia, Malatya, Turkey
  • 1998
    • Oregon Health and Science University
      • Department of Pediatrics
      Portland, Oregon, United States
  • 1995
    • Cincinnati Children's Hospital Medical Center
      • Division of Endocrinology
      Cincinnati, Ohio, United States
    • Karolinska University Hospital
      • Endocrinology Unit
      Tukholma, Stockholm, Sweden
  • 1993
    • Sydney Children's Hospital
      Sydney, New South Wales, Australia
    • National Institutes of Health
      베서스다, Maryland, United States
  • 1991
    • University of Hamamatsu
      Hamamatu, Shizuoka, Japan
    • University of Maryland, Baltimore
      • Department of Medicine
      Baltimore, MD, United States
  • 1989
    • Washington University in St. Louis
      • Department of Pediatrics
      San Luis, Missouri, United States
    • The University of Sheffield
      Sheffield, England, United Kingdom
  • 1988
    • University of Florida
      Gainesville, Florida, United States